Williamson E.J. Walker A.J. Bhaskaran K. Bacon S. Bates C. Morton C.E. et al.

Factors associated with COVID-19-related death using OpenSAFELY.

Nature. 584https://doi.org/10.1038/s41586-020-2521-4Francis A. Baigent C. Ikizler T.A. Cockwell P. Jha V.

The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action.

Kidney Int. 99https://doi.org/10.1016/j.kint.2021.02.003Major R. Selvaskandan H. Makkeyah Y.M. Hull K. Kuverji A. Graham-Brown M.

The Exclusion of Patients with CKD in Prospectively Registered Interventional Trials for COVID-19-a Rapid Review of International Registry Data.

J Am Soc Nephrol. 31: 2250-2252Glenn D.A. Hegde A. Kotzen E. Walter E.B. Kshirsagar A.V. Falk R. et al.

Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease.

Kidney International Reports. https://doi.org/10.1016/j.ekir.2021.02.011Windpessl M. Bruchfeld A. Anders H.J. Kramer H. Waldman M. Renia L. et al.

COVID-19 vaccines and kidney disease.

Nat Rev Nephrol. 17https://doi.org/10.1038/s41581-021-00406-6Krueger K.M. Ison M.G. Ghossein C.

Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation.

Am J Kidney Dis. 75https://doi.org/10.1053/j.ajkd.2019.06.014Walsh E.E. Frenck R.W. Falsey A.R. Kitchin N. Absalon J. Gurtman A. et al.

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

N Engl J Med. 383https://doi.org/10.1056/NEJMoa2027906Attias P. Sakhi H. Rieu P. Soorkia A. Assayag D. Bouhroum S. et al.

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients.

Kidney Int. https://doi.org/10.1016/j.kint.2021.04.009Monin L. Laing A.G. Muñoz-Ruiz M. McKenzie D.R. Del Barrio I.D.M. Alaguthurai T. et al.

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.

Lancet Oncol. https://doi.org/10.1016/S1470-2045(21)00213-8Galipeau Y. Greig M. Liu G. Driedger M. Langlois M.A.

Humoral Responses and Serological Assays in SARS-CoV-2 Infections.

Front Immunol. 11https://doi.org/10.3389/fimmu.2020.610688Rogers T.F. Zhao F. Huang D. Beutler N. Burns A. He W.T. et al.

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.

Science. 369https://doi.org/10.1126/science.abc7520

WHO International Standard for anti-SARS-CoV-2 immunoglobulin.

Lancet. 397: 1347-1348Barda N. Dagan N. Balicer R.D.

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

Reply. N Engl J Med. 384https://doi.org/10.1056/NEJMc2104281Vasileiou E. Simpson C.R. Shi T. Kerr S. Agrawal U. Akbari A. et al.

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.

Lancet. 397https://doi.org/10.1016/S0140-6736(21)00677-2Waldman M. Soler M.J. García-Carro C. Lightstone L. Turner-Stokes T. Griffith M. et al.

Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring.

Kidney Int. 99https://doi.org/10.1016/j.kint.2020.10.032Kronbichler A. Anders H.J. Fernandez-Juárez G.M. Floege J. Goumenos D. Segelmark M. et al.

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases.

Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab064Westra J. van Assen S. Wilting K.R. Land J. Horst G. de Haan A. et al.

Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.

Clin Exp Immunol. 178https://doi.org/10.1111/cei.12390

Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, et al. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv 2021. https://doi.org/10.1101/2021.04.05.21254656.

Spiera R. Jinich S. Jannat-Khah D.

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.

Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220604Schwotzer N. Kissling S. Fakhouri F.

Letter regarding “Minimal change disease relapse following SARS-CoV-2 mRNA vaccine.

Kidney Int. https://doi.org/10.1016/j.kint.2021.05.006Holzworth A. Couchot P. Cruz-Knight W. Brucculeri M.

Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine.

Kidney Int. https://doi.org/10.1016/j.kint.2021.05.007Komaba H. Wada T. Fukagawa M.

Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.

Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2021.05.006Maas R.J. Gianotten S. van der Meijden W.A.G.

An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.

Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2021.05.003Lebedev L. Sapojnikov M. Wechsler A. Varadi R.L. Zamir D. Tobar A. et al.

Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.

Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2021.03.010Kervella D. Jacquemont L. Chapelet-Debout A. Deltombe C. Ville S.

Minimal change disease relapse following SARS-CoV-2 mRNA vaccine.

Kidney Int. https://doi.org/10.1016/j.kint.2021.04.033Perrin P. Bassand X. Benotmane I. Bouvier N.

Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy.

Kidney Int. https://doi.org/10.1016/j.kint.2021.05.022Rahim S.E.G. Lin J.T. Wang J.C.

A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination.

Kidney Int. https://doi.org/10.1016/j.kint.2021.04.024

Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy.

Kidney Int. https://doi.org/10.1016/j.kint.2021.03.002Tan H.Z. Tan R.Y. Jun Choo J.C. Lim C.C. Tan C.S. Liang Loh A.H. et al.

Is COVID-19 vaccination unmasking glomerulonephritis?.

Kidney Int. https://doi.org/10.1016/j.kint.2021.05.009Anderegg M.A. Liu M. Saganas C. Montani M. Vogt B. Huynh-Do U. et al.

De novo vasculitis after mRNA-1273 (Moderna) vaccination.

Kidney Int. https://doi.org/10.1016/j.kint.2021.05.016Aydin M.F. Yildiz A. Oruc A. Sezen M. Dilek K. Gullulu M. et al.

Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination.

Kidney Int. https://doi.org/10.1016/j.kint.2021.05.001Sekar A. Campbell R. Tabbara J. Rastogi P.

ANCA GLOMERULONEPHRITIS POST MODERNA COVID-19 VACCINATION.

Kidney Int. https://doi.org/10.1016/j.kint.2021.05.017

De Serres G, Billard MN, Gariépy MC, Roy MC, Boucher FD, Gagné H, et al. Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal. Vaccine 2019;37. https://doi.org/10.1016/j.vaccine.2019.07.017.

Kostianovsky A. Charles P. Alves J.F. Goulet M. Pagnoux C. Le Guern V. et al.

Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients.

Clin Exp Rheumatol. : 30

Immune Dysfunction in Uremia 2020.

Toxins. 12https://doi.org/10.3390/toxins12070439

Factors That Influence the Immune Response to Vaccination.

Clin Microbiol Rev. 32https://doi.org/10.1128/CMR.00084-18Udomkarnjananun S. Takkavatakarn K. Praditpornsilpa K. Nader C. Eiam-Ong S. Jaber B.L. et al.

Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis.

J Nephrol. 33https://doi.org/10.1007/s40620-019-00668-1Polack F.P. Thomas S.J. Kitchin N. Absalon J. Gurtman A. Lockhart S. et al.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

N Engl J Med. 383https://doi.org/10.1056/NEJMoa2034577Baden L.R. El Sahly H.M. Essink B. Kotloff K. Frey S. Novak R. et al.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

N Engl J Med. 384https://doi.org/10.1056/NEJMoa2035389Grupper A. Sharon N. Finn T. Cohen R. Israel M. Agbaria A. et al.

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.

Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.03500321Yanay N.B. Freiman S. Shapira M. Wishahi S. Hamze M. Elhaj M. et al.

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.

Kidney Int. https://doi.org/10.1016/j.kint.2021.04.006Billany R.E. Selvaskandan H. Adenwalla S.F. Hull K.L. March D.S. Burton J.O. et al.

Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms.

Kidney Int. https://doi.org/10.1016/j.kint.2021.04.008

Rincon-Arevalo H, Choi M, Stefanski A-L, Halleck F, Weber U, Szelinski F, et al. Impaired antigen-specific memory B cell and plasma cell responses including lack of specific IgG upon SARS-CoV-2 BNT162b2 vaccination among Kidney Transplant and Dialysis patients. medRxiv 2021:2021.04.15.21255550.

Schrezenmeier E, Bergfeld L, Hillus D, Lippert J-D, Weber U, Tober-Lau P, et al. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. medRxiv 2021:2021.03.31.21254683.

Agur T. Ben-Dor N. Goldman S. Lichtenberg S. Herman-Edelstein M. Yahav D. et al.

Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospective cohort study.

Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab155

Sattler A, Schrezenmeier E, Weber U, Potekhin A, Bachmann F, Budde K, et al. Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients. medRxiv 2021:2021.04.06.21254963.

Lacson E, Argyropoulos CP, Manley HJ, Aweh G, Chin AI, Salman LH, et al. Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. medRxiv 2021:2021.04.08.21254779.

Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.

Kidney Int. https://doi.org/10.1016/j.kint.2021.04.010Frantzen L. Cavaille G. Thibeaut S. El-Haik Y.

Efficacy of the BNT162b2 mRNA Covid-19 Vaccine in a hemodialysis cohort.

Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab165Jahn M. Korth J. Dorsch O. Anastasiou O.E. Sorge-Hädicke B. Tyczynski B. et al.

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis.

Vaccines. 9: 360Rodríguez-Espinosa D. Broseta J.J. Maduell Francisco Vera M. José Luis Bedini

Humoral response of mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients.

Kidney Int. https://doi.org/10.1016/j.kint.2021.05.018Longlune N. Nogier M.B. Miedougé M. Gabilan C. Cartou C. Seigneuric B. et al.

High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients.

Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab193Speer C. Göth D. Benning L. Buylaert M. Schaier M. Grenz J. et al.

Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2.

Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.03700321Goupil R. Benlarbi M. Beaubien-Souligny W. Nadeau-Fredette A.-C. Chatterjee D. Goyette G. et al.

Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.

CMAJ. 193: E793-800Simon B. Rubey H. Treipl A. Gromann M. Hemedi B. Zehetmayer S. et al.

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls.

Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab179

Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, et al. Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis. medRxiv 2021. https://doi.org/10.1101/2021.05.06.21256768.

Yi SG, Knight RJ, Graviss EA, Nguyen DT, Ghobrial RM, Gaber AO, et al. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration. Transplantation 2021. https://doi.org/10.1097/TP.0000000000003764.

Chan L. Fuca N. Zeldis E. Campbell K. Shaikh A.

Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in Hemodialysis Patients with and without Prior COVID-19.

Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.04080321

Yau K, Abe KT, Naimark D, Oliver MJ, Perl J, Leis JA, et al. The humoral response to the BNT162b2 vaccine in hemodialysis patients 2021. https://doi.org/10.1101/2021.05.24.21257425.

Strengert M, Becker M, Ramos GM, Dulovic A, Gruber J, Juengling J, et al. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on hemodialysis 2021. https://doi.org/10.1101/2021.05.26.21257860.

Goupil R, Benlarbi M, Beaubien-Souligny W, Nadeau-Fredette A-C, Chatterjee D, Goyette G, et al. Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study. medRxiv 2021:2021.03.30.21254652.

Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S, et al. Hemodialysis Patients Show a Highly Diminished Antibody Response after COVID-19 mRNA Vaccination Compared to Healthy Controls. medRxiv 2021:2021.03.26.21254259.

Prasoppokakorn T. Vanichanan J. Chaiteerakij R. Jutivorakool K. Udomkarnjananun S. Pongpirul K. et al.

A randomized controlled trial of comparative effectiveness between the 2 dose and 3 dose regimens of hepatitis a vaccine in kidney transplant recipients.

Sci Rep. 11https://doi.org/10.1038/s41598-020-80052-3Boyarsky B.J. Werbel W.A. Avery R.K. Tobian A.A.R. Massie A.B. Segev D.L. et al.

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.

JAMA. https://doi.org/10.1001/jama.2021.4385Benotmane I. Gautier-Vargas G. Cognard N. Olagne J. Heibel F. Braun-Parvez L. et al.

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine.

Kidney Int. https://doi.org/10.1016/j.kint.2021.04.005Chavarot N. Ouedrani A. Marion O. Leruez-Ville M. Villain E. Baaziz M. et al.

Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept.

Transplantation. https://doi.org/10.1097/TP.0000000000003784Marinaki S. Adamopoulos S. Degiannis D. Roussos S. Pavlopoulou I.D. Hatzakis A. et al.

Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients.

Am J Transplant. https://doi.org/10.1111/ajt.16607Grupper A. Rabinowich L. Schwartz D. Schwartz I.F. Ben-Yehoyada M. Shashar M. et al.

Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus.

Am J Transplant. https://doi.org/10.1111/ajt.16615Benotmane I. Gautier-Vargas G. Cognard N. Olagne J. Heibel F. Braun-Parvez L. et al.

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients.

Kidney Int. https://doi.org/10.1016/j.kint.2021.03.014Husain S.A. Tsapepas D. Paget K.F. Chang J.H. Crew R.J. Dube G.K. et al.

Post-vaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplants recipients.

Kidney International Reports. https://doi.org/10.1016/j.ekir.2021.04.017Rozen-Zvi B. Yahav D. Agur T. Zingerman B. Ben-Zvi H. Atamna A. et al.

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.

Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2021.04.028Boyarsky B.J. Werbel W.A. Avery R.K. Tobian A.A.R. Massie A.B. Segev D.L. et al.

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.

JAMA. 325: 2204-2206

Ou MT, Boyarsky BJ, Chiang TPY, Bae S, Werbel WA, Avery RK, et al. Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept. Transplantation 2021. https://doi.org/10.1097/TP.0000000000003824.

Cucchiari D. Egri N. Bodro M. Herrera S. Del Risco-Zevallos J. Casals-Urquiza J. et al.

Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.

Am J Transplant. https://doi.org/10.1111/ajt.16701Marion O. Del Bello A. Abravanel F. Couat C. Faguer S. Esposito L. et al.

Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants.

Ann Intern Med. https://doi.org/10.7326/M21-1341Korth J. Jahn M. Dorsch O. Anastasiou O.E. Sorge-Hädicke B. Eisenberger U. et al.

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).

Viruses. 13https://doi.org/10.3390/v13050756Husain S.A. Tsapepas D. Paget K.F. Chang J.H. Crew R.J. Dube G.K. et al.

Post-vaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplants recipients.

Kidney International Reports. https://doi.org/10.1016/j.ekir.2021.04.017Caillard S. Chavarot N. Bertrand D. Kamar N. Thaunat O. Moal V. et al.

Occurrence of severe COVID-19 in vaccinated transplant patients.

Kidney Int. https://doi.org/10.1016/j.kint.2021.05.011Tsapepas D. Paget K. Mohan S. Cohen D.J. Husain S.A.

Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients.

Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2021.05.004Wadei H.M. Gonwa T.A. Leoni J.C. Shah S.Z. Aslam N. Speicher L.L.

COVID-19 infection in Solid Organ Transplant Recipients after SARS-CoV-2 vaccination.

Am J Transplant. https://doi.org/10.1111/ajt.16618Song C.C. Christensen J. Kumar D. Vissichelli N. Morales M. Gupta G.

Early Experience with SARs-CoV-2 mRNA Vaccine Breakthrough Among Kidney Transplant Recipients.

Transpl Infect Dis. e13654Tau N. Yahav D. Schneider S. Rozen-Zvi B. Abu Sneineh M. Rahamimov R.

Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients.

Am J Transplant. https://doi.org/10.1111/ajt.16700

Ali NM, Alnazari N, Mehta SA, Boyarsky B, Avery RK, Segev DL, et al. Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination. Transplantation 2021. https://doi.org/10.1097/TP.0000000000003836.

Meshram HS, Kute VB, Shah N, Chauhan S, Navadiya VV, Patel AH, et al. Letter to Editor: COVID-19 in Kidney Transplant Recipients Vaccinated with Oxford-AstraZeneca COVID-19 vaccine (Covishield): A Single Center Experience from India. Transplantation 2021. https://doi.org/10.1097/TP.0000000000003835.

Del Bello Olivier Marion Audrey Delas Nicolas Congy-Jolivet Magali Colombat Nassim Kamar A. Acute rejection after anti-SARS-CoV-2 mRNA vaccination in a kidney-transplant patient. Kidney International 2021. https://doi.org/10.1016/j.kint.2021.04.025.

Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddy JA, et al. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation 2021;Online First. https://doi.org/10.1097/TP.0000000000003780.

Katerinis I. Hadaya K. Duquesnoy R. Ferrari-Lacraz S. Meier S. van Delden C. et al.

De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients.

Am J Transplant. 11https://doi.org/10.1111/j.1600-6143.2011.03604.xKnoll G.A. MacDonald I. Khan A. Van Walraven C.

Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.

J Am Soc Nephrol. 14https://doi.org/10.1097/01.asn.0000079616.71891.f5Kates O.S. Stohs E.J. Pergam S.A. Rakita R.M. Michaels M.G. Wolfe C.R. et al.

The limits of refusal: An ethical review of solid organ transplantation and vaccine hesitancy.

Am J Transplant. https://doi.org/10.1111/ajt.16472Garcia P. Montez-Rath M.E. Moore H. Flotte J. Fults C. Block M.S. et al.

SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey.

J Am Soc Nephrol. https://doi.org/10.1681/ASN.2021010104Pamplona G.M. Sullivan T. Kotanko P.

COVID-19 Vaccination Acceptance and Hesitancy in Dialysis Staff: First Results From New York City.

Kidney International Reports. 6https://doi.org/10.1016/j.ekir.2021.02.001

VACOLUP – CRMR des maladies auto-immunes de Strasbourg (RESO) n.d. https://maladie-autoimmune.fr/vacolup/ (accessed May 1, 2021).

Kant S. Kronbichler A. Salas A. Bruchfeld A. Geetha D.

Timing of COVID-19 Vaccine in the setting of anti-CD20 Therapy: A Primer for Nephrologists.

Kidney International Reports. https://doi.org/10.1016/j.ekir.2021.03.876Kho M.M.L. Reinders M.E.J. Baan C.C. van Baarle D. Bemelman F.J. Diavatopoulos D.A. et al.

The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant - a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium.

Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab186